Desarrollo. Esta obra se encuentra sujeta a una licencia Creative Commons IGO 3.0 Reconocimiento-NoComercial-SinObrasDerivadas (CC-IGO 3.0 BY-NC-ND) (https://creativecommons.org/licenses/by-ncnd/3.0/igo/legalcode) y puede ser reproducida para cualquier uso no-comercial otorgando el reconocimiento respectivo al BID. No se permiten obras derivadas.Cualquier disputa relacionada con el uso de las obras del BID que no pueda resolverse amistosamente se someterá a arbitraje de conformidad con las reglas de la CNUDMI (UNCITRAL). El uso del nombre del BID para cualquier fin distinto al reconocimiento respectivo y el uso del logotipo del BID, no están autorizados por esta licencia CC-IGO y requieren de un acuerdo de licencia adicional.Note que el enlace URL incluye términos y condiciones adicionales de esta licencia.Las opiniones expresadas en esta publicación son de los autores y no necesariamente reflejan el punto de vista del Banco Interamericano de Desarrollo, de su Directorio Ejecutivo ni de los países que representa. Restaurants and business closuresBars, casinos and clubs have been closed countrywide. Cities locked downOn March 30th, the Government of Belize declared nationwide state of emergency. This went into effect at midnight on April 1st and includes a curfew from 8 :00 pm to 05:00 am every day. SANITARY MEASURES Construction/renovation of hospitals No Recruitment of health workersBelize dispatched a team of 60 Cuban doctors to the country from the Cuban embassy. Treatment to patients without medical insuranceLimited to public hospitals. Suspension of nonessential medical services No Limits to the purchase of basic cleaning and personal hygiene goods No MACROECONOMIC POLICIES Fiscal Tax deferralsThey have been announced but details have not been released.

Introduction Chronic pain is one of the most prevalent pathologies in the world. Treatment with neurostimulators is carried out in the most extreme cases and requires a large investment of resources. In these times of the COVID19 pandemic, we present a comprehensive solution for monitoring this kind of patient, this solution includes the development of a mobile application and a support center for remote monitoring (SCRM). Material and methodology The project was developed according to the scientific evidence in the following phases: (1) Approval in a multidisciplinary clinical committee of implants for chronic pain, (2) Setting up a group of experts, (3) Protocol adaptation for the follow-up of patients with chronic pain to the Smartphone environment, (4) Technology platform adaptation to the clinical protocol (technological environment and workflow between the hospital and the SCRM), and (5) Quality evaluation by survey (quantitative and qualitative) of a small series of patients. Results The application was evaluated by asking for user opinions about design and usefulness with the first implanted patients. Some minor adjustments were made concerning downloadable material and screen color and text. Conclusions Developing a comprehensive solution should be based on scientific principles and in accordance with established protocols. A support center ensures greater adherence for follow-up and better patient care.

Background Acute Kidney Injury (AKI) in patients with multiple myeloma (MM) requiring renal replacement treatment (RRT) is associated with high morbidity and mortality. Early reduction of serum free light chains (FLC) using both targeted therapy against MM and intensive hemodialysis (IHD) may improve renal outcomes. We evaluated the effectiveness of two different RRT techniques on renal recovery in a MM patient population: standard dialysis procedure versus IHD with either PMMA or hemodiafiltration with endogenous reinfusion (HFR). Methods Multicentric retrospective study with severe AKI related to MM, between 2011 and 2018. Twenty-five consecutive patients with AKI secondary of MM requiring RRT were included. Patients that underwent IHD received 6 dialysis sessions per week during the first 14 days (PMMA vs HFR). All patients were diagnosed with de novo MM or first relapsed MM. Primary outcome was renal recovery defined as dialysis-free at six months follow-up. Results A total of 25 patients were included. Seventeen patients received IHD and 8 standard dialysis. All patients were treated with targeted therapy, 84% bortezomib-based. Of the 25 patients included, fourteen (56%) became dialysis independent. We observed a higher proportion of patients who received IHD in the group who recovered kidney function compared to those who remained in HD (92.9% vs 36.4%, p:0.007). In our study, the use of IHD to remove FLC had a statistically significant association with renal recovery compared to standard dialysis group (p = 0.024). Conclusion Early reduction of FLC with IHD as an adjuvant treatment along with MM targeted therapy may exert a positive impact on renal recovery.

La cefalea en racimos es un tipo de cefalea trigémino-autonómica con síntomas marcadamente disfuncionales debidos al intenso dolor y a la aparición de signos disautonómicos hemicraneales ipsilaterales recurrentes. El tratamiento médico no siempre resulta eficaz o puede no tolerarse debido a sus efectos adversos. El desarrollo de técnicas quirúrgicas que inciden en el tratamiento a través de la estimulación de estructuras directamente relacionadas con el dolor, supone una nueva  y esperanzadora herramienta terapéutica para este tipo de pacientes. Además de una cirugía correcta, el tipo de anestesia para la intervención debe ser cuidadosa y adecuarse a la necesidad de trabajar sobre un campo quirúrgico oro-facial amplio. Presentamos dos casos de pacientes con cefalea en racimos de evolución crónica y refractaria a tratamiento, sometidos a la implantación quirúrgica de un microestimulador en el ganglio esfenopalatino bajo anestesia general. ABSTRACT Sphenopalatine ganglion microstimulator surgical insertion. Anesthetic management and literature review Cluster headache is a trigeminal-autonomic headache with severe symptoms due to recurrent intense pain and ipsilateral autonomic manifestations. Medical treatment is not always succesful or may be poorly tolerated for side effects. The development of surgical technics who involve the stimulation of the pain centers, is a new and hopeful tool for these patients. Althought a correct surgery, anesthesia may be careful and must fit into a board surgical orofacial field. We expose a case for chronic and refractory cluster headache, treated by sphenopalatine ganglion microstimulator surgical insertion under general anesthesia.

INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic raises many questions about the management of patients with significant comorbidities. Hematologic patients are usually fragile due to an important immunosuppression, so the impact of coronavirus disease (COVID-19) is yet to be determined. MATERIALS AND METHODS: We conducted a single-center retrospective observational study of patients with hematologic malignancies diagnosed with SARS-CoV-2 at Vall d´Hebron University Hospital (HUVH) between March 1st and May 31st 2020 to analyze their clinical characteristics and evolution. Patient's demographic data, underlying pathology, signs and symptoms of COVID-19, treatment received and clinical course were collected. A statistical analysis was performed to identify the possible variables associated with COVID-19 mortality. For this purpose, we used univariate and multivariable logistic regression models. RESULTS: We identified 70 patients with PCR confirmed SARS-CoV-2 infection and hematologic malignancy. The median age was 75 years (range 22-91), and 44% were female. The majority (74%) had evidence of active malignancy and 53% were receiving active therapy. Lymphoid pathology (73%) predominated over myeloid. The median number of previous lines of treatment was 0 (range 0-6), 23% had received at least 2 lines, whereas 10% underwent hematopoietic stem cell transplantation (HSCT) (5 patients allo-HSCT, 2 auto-HSCT). Half of the patients had more than one pre-existing comorbidity (17% obstructive pulmonary disease). At diagnosis the most common symptoms were fever (76%), cough (60%) and dyspnea (31%). We observed that 58% of patients presented a chest X-ray compatible with COVID-19. Regarding laboratory parameters, stood out lymphopenia (65% of patients presented <1200 lymphocytes/mm3) and elevation of inflammation parameters, such as D-dimer (median 365 ng/mL, range 50-5860), ferritin (median 1063 ng/mL, range 73-14191), IL-6 (median 59,6 pg/mL, range 3-4079) and PCR (median 11,2 mg/dL, range 0,3-79,9). Empirical therapy for COVID-19 included antibiotics (78%), anti-virals (50%, 3% remdesivir), and hydroxychloroquine (88%). Only 24% received tocilizumab, 50% heparin (33% prophylactic dose), 12% G-CSF, 9% norepinephrine, 4% corticosteroids and 1% ß-IFN. Most of patients (73%) required oxygen therapy: 36% high-flow, 29% low flow and 8% endotracheal intubation. There were 6 patients who did not receive any treatment. COVID-19 was acquired via nosocomial infection in 23% of patients, 91% of them requiring hospitalization, 14% in the Intensive Care Unit (ICU). The median days of hospitalization since diagnosis was 17 (range 3-55). The case fatality rate (CFR) from COVID-19 was higher in hematologic patients than the one observed in non-hematologic patients at the HUVH (figure 1), being of 41% at 11 days from diagnosis. CFR was higher in patients older than 75 years old (61%), while the mortality among patients receiving active therapy was 42%. The main cause of death was acute respiratory failure (93%). In the univariate logistic regression model, age >75 years (OR 1.07; p=0.008), active malignancy (OR 5; p=0,02), >1 comorbidity (OR 5.3; p=0,049) and high levels of IL-6 (OR 8.2; p= 0.005) were statistically significant. In the multivariable logistic regression model, age ≥75 years (OR 4.4; p=0.01) and IL-6 levels at baseline > 59.6 pg/mL (OR 7.2; p=0.01) were associated with a higher mortality (table 1). The presence of an active malignancy was not a significant variable in the multivariable logistic regression model. CONCLUSIONS: Patients with hematologic malignancies and COVID-19 presented similar symptoms, signs and radiological characteristics to those described in the general population at diagnosis. In our cohort, advanced age and high IL-6 values were associated with higher mortality. Furthermore, it was observed that active hematologic disease is a factor of poor prognosis of COVID-19. Disclosures Salamero: Daichii Sankyo:Honoraria;Celgene:Consultancy, Honoraria;Novartis:Consultancy, Honoraria;Jazz Pharmaceuticals:Consultancy, Honoraria;Pfizer:Consultancy.Abrisqueta:Janssen:Consultancy, Honoraria, Speakers Bureau;AbbVie:Consultancy, Honoraria, Speakers Bureau;Roche:Consultancy, Honoraria, Speakers Bureau;Celgene:Consultancy, Honoraria.Bosch:Hoffmann-La Roche:Research Funding.